Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
AssigneeMerck & Co., Inc.
InventorsFrank L. Graham, Robin Parks
Life of this patent
Estimating the term…
Loading patent…
AssigneeMerck & Co., Inc.
InventorsFrank L. Graham, Robin Parks
Estimating the term…
This invention responds to a long felt need, by providing in one embodiment, a helper virus based on the Ad2 serotype for use in the Cre/loxP system for the generation of Ad vectors deleted of all Ad protein coding sequences. Using this and helper virus based on Ad5, genetically identical hdAd that differ only in the virion protein components, which are derived from the helper virus, were produced. The vectors have identical expression characteristics in vitro, regardless of the serotype, and the sequential use of hdAd of different serotypes allows for successful repeat vector administration in vivo.
An adenoviral vector gene delivery system comprising:
A method of making a series of genetically identical adenoviral vectors wherein each member of said series has a different serotype, for delivering and expressing a desirable gene in a recipient of said series of genetically identical adenoviral vectors, which comprises:
A kit comprising:
Dependencies are inferred from the claim text.